Bavarian Nordic ramps up monkeypox vaccine production

CEO Paul Chaplin reports that Bavarian is making more doses of its vaccine against monkeypox due to the recent outbreak.

Paul Chaplin, CEO of Bavarian Nordic | Photo: Bavarian Nordic /PR

Bavarian Nordic can currently boast that it is the only firm in the world to have an approved vaccine against infectious disease monkeypox. The current outbreak has turned the spotlight onto the Danish biotech company, which can no longer keep up with demand for its vaccine.

Consequently, the production of the monkeypox vaccine has to be kicked up a gear, according Bavarian CEO Paul Chaplin, speaking to The Wall Street Journal. He says that a number of countries have requested the vaccine but that Bavarian Nordic has limited supplies left. Bavarian therefore intends to make more.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs